Astellas Pharma Germany Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…
International Pharmaceutical Manufacturing Gr Although Indonesia in the last ten years had the second highest growth in ASIA in terms of drugs’ production and consumption, the market share of research based companies has dropped from 50% to 25%. What have been the main drivers leading to the current scenario? The share of international companies…
generics “The ball is in the hands of the government,” according to Giorgio Foresti, general manager of Ratiopharm. “Once aware of the opportunities created by generics, politicians will have to make hard decisions.” Until now, generics prescriptions were limited by strong links between innovators and doctors, and price alignment trends reducing…
Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Russia. Prepared in association with Lidings, a leading global law firm, this is an extract from The Pharma Legal Handbook: Russia, available to purchase here for GBP 99. 1. What is the definition of Rare Diseases…
Pharma Legal Handbook The ins and outs of traditional medicines and OTC products in Greek pharma. Prepared in association with Calavros Law Firm, a leading global law firm, this is an extract from The Pharma Legal Handbook: Greece, available to purchase here for USD 99. 1. What are the regulatory requirements for traditional, herbal, complementary,…
See our Cookie Privacy Policy Here
